Revenue of $640M! First Global TIL Cell Therapy's Q3 PerformanceFinancial statementsOn November 7, local time, Iovance, a global leader in TIL (Tumor Infiltrating Lymphocytes) cell drug development, released its Q3 financial results. TIL therapy, Amtagvi? (Lifileucel), continues strongly, with total product revenue reaching $58.6M (approximately ￥640 million) in Q3 2024.
EN
Agricultural News
Food News
Industrial News
Cosmetic News
Pharmaceutical News
Science News
